CDER announces new guidance agenda for 2025
Regulatory NewsJoanne S. Eglovitch
Advertising, Promotion and LabelingAntimicrobial resistanceAudit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyCDERChemistry, Manufacturing and Controls (CMC)Clinical TrialsCombination productsCombination products/companion diagnosticsCTD/eCTDDrug master file (DMF)EnforcementGenericsGMPGuidanceICHLeadershipManufacturingPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)